LEVRONC®

REG. SAN. NO. INVIMA:
INVIMA 2017M-007759

PRINCIPIO ACTIVO:
Levocloperastina fendizoato 35,4 mg/5mL

UNIDAD DE VENTA:
Con fórmula facultativa

Referencias

  • 1. Aliprandi P. et al. Levocloperastine in the treatment of chronic nonproductive cough: comparative efficacy versus standard antitussive agents. Drugs Exp Clin Res. 2004.
  • 2. Aliprandi P. et al. Therapeutic Use of Levocloperastine as an Antitussive Agent. Clinical Drug Investigation. el 1 de abril de 2002.
  • 3. Satish K, Sholapuri D, Niranjane V, Garg S. Efficacy and Safety of Levocloperastine in the Treatment of Dry Cough: A Prospective Observational Study. J Assoc Physicians India 2018.